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Spinal muscular atrophy (SMA) is a recessive neuromuscular disease caused by mutations in the human sur-
vival motor neuron 1 (SMN1) gene. The human SMN protein is part of a large macromolecular complex
involved in the biogenesis of small ribonucleoproteins. Previously, we showed that SMN is a sarcomeric
protein in flies and mice. In this report, we show that the entire mouse Smn complex localizes to the sarco-
meric Z-disc. Smn colocalizes with a-actinin, a Z-disc marker protein, in both skeletal and cardiac myofibrils.
Furthermore, this localization is both calcium- and calpain-dependent. Calpains are known to release pro-
teins from various regions of the sarcomere as a part of the normal functioning of the muscle; however,
this removal can be either direct or indirect. Using mammalian cell lysates, purified native SMN complexes,
as well as recombinant SMN protein, we show that SMN is a direct target of calpain cleavage. Finally, myo-
fibers from a mouse model of severe SMA, but not controls, display morphological defects that are consistent
with a Z-disc deficiency. These results support the view that the SMN complex performs a muscle-specific
function at the Z-discs.
INTRODUCTION
Loss-of-function mutations in the human survival motor
neuron 1 (SMN1) gene result in spinal muscular atrophy
(SMA), a devastating neuromuscular disorder. SMN1 is cur-
rently the only gene known to cause SMA, however,
roughly 4% of the cases are unlinked to this locus (1). SMN
protein is predominantly found as a part of a large macromol-
ecular complex, consisting of nine different proteins: SMN,
Gemins 2–8 and UNRIP/STRAP (2,3). SMN is involved in
essential housekeeping functions as well as tissue-specific
ones (4–7). These include biogenesis of small nuclear ribonu-
cleoproteins (snRNPs), transcription, pre-mRNA splicing,
axonal mRNA transport, neurite outgrowth, neuromuscular
junction (NMJ) formation, myoblast fusion and myofibrillo-
genesis (8–23). A common theme among many of these pro-
cesses is the actin cytoskeleton, however, the molecular details
by which loss of SMN function results in SMA are not known.
Although a majority of studies have focused on roles for
SMN in motoneurons, SMA patients display a pattern of
muscle weakness that is more reminiscent of a myopathic dis-
order than a neurogenic one (4). SMN-depleted myoblasts
from humans and mice show marked defects in fusion and pro-
liferation (12,15). Moreover, co-cultures of SMA patient-
derived muscle cells with wild-type motoneurons revealed
that SMN expression in muscle is required for maintaining
stable innervation (24,25). However, transgenic experiments
in flies (17) and mice (26) have shown that SMN expression
in muscle does not ameliorate the phenotype in the absence
of neuronal co-expression. Overexpression of SMN in
neurons alone also does not rescue the SMA phenotype
(17,26). Thus SMA might not be a cell-autonomous disease.
The observed motor defects could be caused by primary
abnormalities in both muscles and motoneurons, or perhaps
due to a failure of communication between these two
†The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors.
To whom correspondence should be addressed at: Department of Biology, University of North Carolina, 415 Fordham Hall, CB#3280, Chapel Hill,
NC 27599-3280, USA. Tel: þ1 9199622770; Email: agmatera@email.unc.edu
# The Author 2008. Published by Oxford University Press. All rights reserved.
For Permissions, please email: journals.permissions@oxfordjournals.org
Human Molecular Genetics, 2008, Vol. 17, No. 21 3399–3410
doi:10.1093/hmg/ddn234
Advance Access published on August 8, 2008
tissues. Indeed, SMA has recently been described as an NMJ
synaptopathy (27,28). Clearly, a better understanding of
SMN’s role(s) in muscle cell function will help to distinguish
among these possibilities.
Muscle fibers (myofibers) are composed of bundles of
contractile filaments, termed myofibrils. At the ultrastructural
level, each myofibril consists of hundreds of individual con-
tractile units, called sarcomeres. Sarcomeres work in tandem
to produce the mechanical force of muscle contraction.
Within each sarcomere is an actin-rich I-band that is bisected
by the Z-disc (or Z-line) and a myosin-rich A-band that is
bisected by the M-line (29). The boundaries of each sarcomere
are defined by the Z-discs, which function to interlock adja-
cent sarcomeres and to anchor the actin-rich thin filaments.
Myofibrillar dynamics at the Z-discs and overall muscle main-
tenance are regulated by two distinct proteolytic pathways, the
calcium-dependent calpain system and the ubiquitin protea-
some system (30,31). Disruptions within both of these proteo-
lytic pathways have been linked to a number of muscular
disorders (32–35).
The ubiquitin proteasome is the principal pathway involved
in muscle growth, remodeling and atrophy (36,37). Although
the proteasome is the final degradative mechanism utilized
by muscle during wasting, it is clear that additional proteolytic
systems operate upstream to disassemble the sarcomere, as
proteasomes are not able to degrade intact myofibrils (38).
Calpain-mediated proteolysis is important in this regard, and
this pathway also contributes to muscle protein breakdown
and remodeling under catabolic conditions (37,39,40). Thus
calpains are calcium-dependent proteases that act upstream
of the proteasome to release proteins from the myofibrillar
Z-disc (40–42).
We recently reported that reduced expression of dSMN
within the adult Drosophila thorax results in severe neuromus-
cular dysfunction, with prominent myofibrillogenesis defects
(9). Surprisingly, we found that SMN is a sarcomeric protein
that forms a complex with a-actinin and colocalizes at the
Z-discs of both Drosophila and mouse myofibrils. Here, we
show that the entire Smn complex localizes to the Z-discs of
wild-type mouse myofibrils. Furthermore, Smn is present at
the Z-disc in both skeletal and cardiac muscles and, interest-
ingly, this localization is both calcium- and calpain-dependent.
In accordance with the view that calpains regulate Z-disc
protein turnover (31), we also demonstrate that Smn is a
direct target of calpain cleavage in vitro and in vivo. Impor-
tantly, myofibers from a mouse model of SMA, but not con-
trols, display morphological defects that are consistent with
a Z-disc deficiency. Taken together with the fact that calpains
are regulatory proteases with functions in diverse cell types,
the results have direct implications not only for muscle-
specific functions of SMN but also for neuronal ones as well.
RESULTS
Smn localization in striated muscle
Previously, we showed that Smn localizes to the sarcomeres of
native Drosophila and purified mouse striated muscle myofi-
brils (9). Although there was some variability in the
anti-dSMN staining patterns of the native Drosophila myofi-
brils (i.e. those that are mechanically teased apart), the more
highly purified mouse myofibrils (see Materials and
Methods) showed prominent Z-disc anti-Smn staining (9).
We therefore investigated the distribution of Smn in native
myofibers and purified myofibrils from wild-type mice
(Fig. 1). Similar to the situation in Drosophila, we observed
two different patterns of Smn staining in the native mouse
fibers: granular and striated (Fig. 1A and B). In the majority
of muscle fibers, the granular staining pattern was predomi-
nant (Fig. 1A), whereas in a subset of fibers, a more striated
pattern was revealed (Fig. 1B). A significant amount of
diffuse Smn signal was overlaid upon both of the patterns
(Fig. 1A and B). We hypothesized that the diffuse and granular
staining was primarily due to sarcoplasmic signal and that
removal of this material would allow better visualization of
the sarcomeric Smn protein. Consistent with this interpret-
ation, Smn was found to localize in a distinctly striated
pattern throughout the length of the myofibrils following the
purification procedure (Fig. 1C). Importantly, western blot
analysis (Fig. 1D) demonstrated the presence of Smn in puri-
fied myofibrils and confirmed the specificity of the Smn signal
observed by immunostaining. Thus, Smn localizes in a sarco-
meric pattern on mouse skeletal muscle myofibrils.
The Z-disc, which marks the boundary of each sarcomere, is
composed of many different components, several of which
localize to multiple subsarcomeric compartments (43). Thus
we wanted to determine whether Smn colocalized with other
known Z-disc proteins. a-Actinin plays an important role in
Figure 1. Smn localizes to skeletal myofibrils. Mouse muscle fibers and
purified myofibrils were subjected to immunofluorescence imaging (average
projection of a Z-stack of 13 focal planes, imaged at 0.5 mm per section)
and western blotting. Antibodies against Smn (mAb Clone 8) were used to
stain muscle fibers (A, B) and purified myofibrils (C); scale bar represents
10 mm. The presence of Smn was verified by western blot of whole muscle
lysate and purified myofibrils (D).
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the sarcomere as an actin filament cross-linker and is often
used as a Z-disc marker. Because we previously observed
that Smn colocalizes with a-actinin in mouse skeletal
muscle myofibrils (9), we tested whether this colocalization
also occurs in cardiac myofibrils, especially given the fact
that both acute and chronic SMA patients are reported to
have cardiac problems (see Discussion). As shown in
Figure 2, Smn colocalizes with a-actinin in purified myofibrils
from both skeletal and cardiac muscles. We conclude that Smn
localization to the Z-disc of striated muscles is a conserved
feature among metazoans.
Smn complex is a component of the Z-disc
Smn forms a large, oligomeric complex with at least eight
other binding partners, collectively known as Gemins (2,3).
In order to determine whether Smn was present in the sarco-
mere as part of a larger complex, we investigated the sarco-
meric localization of Gemins 2–6 and 8, as well as that of
Unrip, another integral member of the Smn complex (44–
52). Each of the Gemins we tested, with the possible exception
of Gemin 5, colocalized precisely with Smn in skeletal muscle
myofibrils (Fig. 3 and data not shown). Although it was
certainly detectable, the Gemin 5 staining was weaker than
that of the other Gemins (data not shown). Furthermore, con-
sistent with the cytoplasmic origin of the myofibril, we found
that Unrip, a protein that copurifies with the Smn complex
preferentially in the cytoplasm of other cell types (45,46)
also colocalized with Smn at the Z-disc (Fig. 3). Although
colocalization does not necessarily mean these factors are
complexed together at the Z-disc, the most parsimonious
interpretation of the data leads us to conclude that the entire
cytoplasmic Smn complex is a part of the sarcomeric Z-disc
ensemble.
U snRNPs do not localize to sarcomeres
The function of the Smn complex in cytoplasmic assembly and
nuclear import of Sm-class snRNPs is well documented
(14,22,23,53,54). However, Sm-class snRNPs are not
thought to be a part of the muscle myofibril. To confirm the
absence of splicing snRNPs from the myofibril preparations,
we used three markers: U2B00, a protein specific to the U2
snRNP, SmB, a member of the spliceosomal Sm core, and
the trimethylguanosine (TMG) cap, a structure common to
all mature Sm-class snRNPs. Antibodies targeting a non-
muscle protein, neurofilament-L, were used as a negative
control; actin (visualized by phalloidin) was used as a
positve control. When purified skeletal muscle myofibrils
were probed using antibodies targeting these markers, no
specific signals were detected (Fig. 4). These findings are
therefore most consistent with a function for sarcomeric
Smn that is muscle-specific and not related to its role in spli-
ceosomal snRNP biogenesis.
Smn is removed from myofibrils by calcium
or calpain treatment
Calpains are thought to be regulatory proteases (as opposed to
degradative ones) and are essential for numerous cellular pro-
cesses virtually in every tissue in the body, including muscle
(55–57). The ubiquitous calpains 1 and 2, as well as the
muscle-specific isoform, calpain 3, are involved in aspects of
muscle maintenance, including myofibril degeneration and
sarcomeric remodeling (31,42,58). Increasing the endogenous
calpain activity with calcium is known to trigger disassembly
of the sarcomere, including removal of Z-disc proteins such as
a-actinin (59–62). To test whether Smn could be removed by
these procedures, muscle tissue was incubated overnight in
Ringer’s buffer that contained either 10 mM Caþþ or 1 mM
ethylene glycol tetraacetate (EGTA) (control). Myofibrils
were then purified by standard procedures and analyzed by flu-
orescence microscopy. As shown in Figure 5A (upper panels),
the control myofibrils remained intact, as visualized by Z-disc
staining with Smn or a-actinin. The calcium-treated prep-
arations showed loss of the signals for both Smn and
a-actinin (Fig. 5A, lower panels).
Although suggestive of calpain activity, the previous results
demonstrate that endogenous proteases are responsible for the
removal of Smn and a-actinin from the Z-disc. In order to test
whether calpain activity is required, we purified myofibrils
under standard conditions and then treated them with or
without exogenous calpain for 20 min at room temperature
(RT). Figure 5B clearly shows that calpain treatment
removed Smn from the Z-discs, leaving the myofibrils intact
(as evidenced by the actin counterstain).
Smn is a direct target of calpain-mediated
proteolytic cleavage
Calpains can remove Z-disc proteins from myofibrils either by
direct cleavage of the target protein or indirectly by cleavage
of an interacting partner. For example, calpain treatment of
myofibrils is known to remove a-actinin from the Z-disc,
but calpains do not directly target skeletal muscle a-actinin
for cleavage (62). We therefore assayed whether SMN was a
direct target of calpain. We incubated purified native human
SMN complexes or recombinant SMN/Gemin 2 heterodimers
in the presence or absence of calpain and analyzed the clea-
vage products by western blotting with N- and C-terminal-
specific anti-SMN monoclonal antibodies. As shown in
Figure 2. Smn localizes to the Z-discs of striated muscle. Purified myofibrils
from skeletal and cardiac muscle were co-stained with antibodies against Smn
and the Z-disc protein a-actinin; the scale bar for skeletal myofibrils is 10 and
5 mm for cardiac myofibrils.
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Figure 6, a 28 kDa N-terminal SMN cleavage product and a
10 kDa C-terminal product were detected only upon addition
of calpain. The N-terminal fragments were visualized using a
commercial anti-SMN monoclonal antibody (Clone 8, BD
Biosciences) that recognizes residues mapping within human
exon 2B, whereas the C-terminal fragments were detected
Figure 3. Smn complex is present at Z-Discs. Purified mouse hindlimb skeletal myofibrils were co-stained with antibodies against Smn and Gemins 2–4, 6 and
Unrip. Because the anti-Gemin 3 antibody (mAb 12H12) does not cross-react with mouse, but does cross-react with the hamster protein (http://www.abcam.com/
index.html?datasheet=10305), purified myofibrils from hamster hindlimb were used for the Gemin 3 panel. Scale bar represents 5 mm.
Figure 4. U snRNPs do not localize to myofibrils. Purified skeletal myofibrils were co-stained with an antibody against the U2-specific protein, U2B0 0, an
antibody specific to the U snRNP Sm core (mAb Y12), an Sm-core protein, SmB (mAb 12F5) and an antibody specific to the U snRNP 50-TMG cap, TMG
(mAb K121) (A–C). The myofibrils were counter stained with phaloidin conjugated with FITC. A negative control antibody (neurofilament-L) was also
used on purified myofibrils (D); scale bars represent 10 mm.
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using a monoclonal antibody (mAb 9F2) that recognizes resi-
dues near the polyproline motif in exon 5 (Supplementary
Material, Fig. S1 and L. Pellizzoni, unpublished data).
Notably, glutathione-s-transferase (GST)-Gemin 2, which was
co-expressed in the bacteria expressing His-SMN, was unaf-
fected by the calpain treatment (Fig. 6). Similarly, native
Gemin 2 was also uncleaved when purified SMN complexes
were treated with calpain (Fig. 6). We conclude that calpain
is necessary and sufficient for cleavage of SMN in vitro.
Cleavage of SMN was inhibited by addition of
N-acetyl-leucyl-leucyl-norleucinal (ALLN), a synthetic inhibi-
tor of calpain and other neutral cysteine proteases. Purified
native SMN complexes (Fig. 7A) or cellular lysates (Sup-
plementary Material, Fig. S2) were treated with calpain in
the presence or absence of the ALLN peptide. In the presence
of ALLN, no cleavage product was detected. Titration of the
reaction showed that the appearance of the 28 kDa cleavage
product and disappearance of the full-length protein was
dependent upon the amount of added calpain (Fig. 7B). At
very high concentrations of calpain, the full-length SMN
protein was fully cleaved and shorter, secondary SMN clea-
vage products were also detected (Fig. 7B). Thus calpain
targets SMN in the context of the native complex.
To examine whether SMN cleavage could be detected in vivo,
we incubated total HeLa cell lysates with or without added
calcium and/or calpain. Importantly, we found that addition of
1 mM Caþþ to the lysate was sufficient to induce SMN cleavage,
presumably by endogenous calpains (Fig. 7C, lane 2). Incubation
of control lysates with exogenous calpain but without added
Caþþ also showed no cleavage (Fig. 7C, lane 3). When lysates
were incubated in 1 mM Caþþ along with exogenous calpain,
SMN cleavage was nearly complete (Fig. 7C, lane 4). Note that
10-fold higher concentrations of exogenous calpain were
used in the reactions performed on total cellular lysates than on
those using purified SMN proteins (recombinant or native). The
fact that the same-sized cleavage products were detected in the
presence or absence of added calpain (Fig. 7C) suggests that
SMN is a target of calpain cleavage in vivo.
We also assayed for cleavage of other members of the SMN
complex by calpain. Western blotting for SMN, Gemins 2–8
and Unrip following treatment of either HeLa lysate or puri-
fied native SMN complexes with calpain showed that Gemin
5 was cleaved in both HeLa lysate and the purified SMN
complex. In contrast, Gemin 3 cleavage was only detected
when the purified complex was used as the substrate
(Fig. 8). Other members of the SMN complex were relatively
unaffected. Unfortunately, we were unable to detect the
10 kDa C-terminal cleavage products in total HeLa lysate
using mAb 9F2 (data not shown). Although we have not
measured the stability of the SMN cleavage products in
HeLa lysate, it is likely that these products are ultimately
degraded. We were similarly unable to detect endogenous
SMN cleavage products in wild-type mouse muscle tissues
(data not shown). Thus, the steady-state level of these proteo-
lytic isoforms of SMN is likely to be quite low.
Myofibrillar defects in a mouse model of severe SMA
To determine whether reduced Smn expression leads to sarco-
meric defects, we investigated the integrity of skeletal muscle
myofibrils in the severe hypomorphic background of SMA
type I mice (Smn2/2;SMN2þ/þ). These animals recapitulate
much of the human SMA pathology and are characterized
by reduced size, proximal muscle paralysis and a general
failure to thrive (63,64). As shown in Figure 9A, the mutant
pups were significantly smaller than their wild-type littermates
at postnatal day 5 (P5) and the amount of Smn protein in skel-
etal muscle lysates of the SMA mice was dramatically reduced
(Fig. 9B). Myofiber preparations from wild-type and SMA
mutant mice were stained with antibodies targeting the
Z-disc marker protein, a-actinin, and imaged in 3D by
laser-scanning confocal microscopy. Two-dimensional (2D)
views of 3D data sets (average intensity projections) are
shown in Figure 9C. The images reveal that wild-type myofi-
brils contain the expected ordered sarcomeric staining pattern
throughout their lengths, whereas the SMA mutant muscles
Figure 5. Calpain activity removes Smn from myofibrils. Increased endogen-
ous calpain activity was indirectly assessed by incubating skeletal muscle
tissue either in a buffer with 10 mM calcium, which activates calpain, or in
a buffer lacking calcium; purified myofibrils were either stained with anti-
bodies against Smn or a-actinin as a positive control (A). Exogenous
calpain 1 was incubated with purified skeletal myofibrils (controls were incu-
bated without added calpain) and co-stained with antibodies against Smn and
conjugated phalloidin (B). Scale bars 10 mm.
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exhibit numerous morphological defects, including vacuoles
(Fig. 9C, arrows), wave-like lobulations (Fig. 9C, stars) and
altered Z-disc spacing (Fig. 9C, arrowheads). The ‘wavy’
myofibers and associated a-actinin negative vacuolar areas
in the SMA type I muscles are reminiscent of the phenotype
seen in the Drosophila model of SMA (9). The vacuolar
areas lacking a-actinin may represent focal dissolution of
the myofibrils, one of the key features found in myofibrillar
myopathies (65–67). Although the vacuoles are invariably
associated with convolutions of the myofiber, the Z-disc mal-
formations include occasional streaming and variations in
spacing that indicate an overall loss of sarcomeric uniformity
(Fig. 9C). Consequently, many sarcomeres are out of align-
ment with their neighbors and appear to be either over-
stretched or reduced in length. Whether this phenotype is
primarily myopathic or if it is a secondary consequence of
denervation is not known and remains to be determined.
However, these results establish that myofibrils from SMA
type I mice display defects that are consistent with those
observed in other myopathies (65,67–73).
DISCUSSION
Role of the Smn complex in the sarcomere
We have shown that the entire cytoplasmic Smn complex
localizes to the sarcomeric Z-disc in both cardiac and skeletal
myofibrils of the mouse. Numerous case reports have
suggested congenital heart defects in SMA patients (74–80).
Our discovery that SMN is a sarcomeric protein provides a
plausible explanation for the observed cardiac involvement
in SMA. We speculate that SMN performs a tissue-specific
function in striated muscles because spliceosomal snRNPs
and related protein factors do not localize to purified myofi-
brils. Thus it is unlikely that the sarcomeric SMN complex
participates in snRNP biogenesis. Instead, we suggest three
Figure 6. Calpain directly cleaves SMN in vitro. To verify that calpain cleaves SMN directly, purified SMN complexes or recombinant His-SMN/GST-Gemin 2
heterodimers were incubated with 0.06 and 0.15 U of calpain, respectively. Antibodies recognizing the N- (Clone 8) and C-terminal (mAb 9F2) domains of SMN
were used to visualize the two fragments of SMN from the purified SMN complexes. His-probe reagent was used to visualize recombinant His-SMN.
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non-mutually exclusive possibilities for SMN function in
the sarcomere: maintenance of Z-disc integrity, signaling to
nucleus, and mRNP transport.
The alignment of sarcomeres between adjacent myofibrils
provides a means to coordinate contractions between individual
myofibrils. This precise alignment is accomplished by a
complex network of protein–protein interactions within and
physically linked to the Z-disc (29). The Z-discs also link
peripheral myofibrils to the nuclear membrane, to the sarco-
lemmal costameres and to the mitochondria. These lateral
associations are mediated by intermediate filaments and associ-
ated cytoskeletal proteins such as desmin, vinculin, plectin and
alpha-B crystallin (29). It is interesting to note that SMN has
been shown to form complexes with a-actinin (9) and
alpha-B crystallin (81). Given the sarcomeric malformations
observed in the muscles of SMA type I mice (Fig. 9), it is
possible that the sarcomeric SMN complex is involved in
Z-disc homeostasis.
Figure 7. Calpain inhibition, titration and endogenous activation. Purified
native SMN complexes were treated with calpain (0.05 U) or with calpain
and ALLN inhibitor. The cleavage of SMN was compared with an undigested
control lane (A). Increasing amounts of calpain (0.003 to 3.0 U) were incu-
bated with purified SMN complexes and the cleavage profile of SMN was ana-
lyzed (B). Western blotting was performed on HeLa lysates using anti-SMN
(Clone 8) antibodies. In lanes 2 and 4, 1 mM calcium was added to the
lysates. In lanes 3 and 4, 1.5 U of calpain were added. Lysates were incubated
for 15 min. at 308C and SMN cleavage profiles were compared with the
control (lane 1) (C).
Figure 8. Calpain cleaves a subset of the Gemins within the SMN complex
in vitro and in vivo. HeLa lysate and purified SMN complexes were treated
with exogenous calpain, 1.4 and 0.06 U, respectively. Western blotting was
performed with antibodies to each member of the SMN complex. Note
control and calpain lanes in the Gemin 5 and Gemin 3 panels.
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In addition to its canonical roles in anchoring actin fila-
ments and transmitting the contractile force, the Z-disc has
recently emerged as a platform for intracellular signaling
(82,83). The SMN complex localizes to both the nucleus and
cytoplasm of many cell types, including muscles. SMN is
known to interact with components of the epidermal growth
factor receptor signaling pathway (84–86) and is, therefore,
a candidate Z-disc signaling factor.
Cell types with vast cytoplasmic extensions, such as
muscles and neurons, face tremendous challenges in maintain-
ing the asymmetric protein distributions required for proper
functioning of these highly specialized cells. Localized trans-
lation is thought to be important for setting up these cellular
asymmetries. Previous work has shown that the Smn
complex colocalizes with b-actin mRNP granules in axons
and growth cones of motoneurons and that reduced Smn
expression correlates with a reduction in b-actin protein and
mRNA staining at these distal sites (11,19). Thus SMN is
thought to play a role in the assembly, transport and/or local-
ization of b-actin mRNP complexes. We hypothesize that Smn
plays a similar role in the transport and localized translation of
mRNPs in muscle cells. In support of this model, Morris and
Fulton (87) showed that three different Z-disc associated pro-
teins (desmin, vinculin and vimentin) colocalize with their
respective mRNAs in a striated pattern in primary cultures
of embryonic chicken skeletal muscle. Similar to b-actin
(88), vimentin mRNA is also thought to contain an mRNA
‘zipcode’ that targets the mRNP to a specific subcellular
locale (89,90). Interestingly, a protein that binds to the vimen-
tin mRNA zipcode (EF-1g) is known to copurify with Z-disc
proteins MuRF1 and MuRF2 (91). Thus it is plausible that
localized translation takes place within the sarcomeric
Z-disc. In light of the putative role for the SMN complex in
mRNP transport (11) and its demonstrated localization to the
Z-disc (9), SMN’s sarcomeric function may be regulated by
calcium and/or calpain.
Calpain cleavage of SMN: functional implications
We have shown that SMN is a direct target of calpain cleavage
in vitro and in vivo. As mentioned earlier, calpain is a regulatory
protease, whose action typically activates or inactivates a given
protein target; calpain activity is compartmentalized and works
in microenvironments where the Caþþ flux can be controlled.
Calpains 1 and 2 are ubiquitously expressed and share a
common subunit, calpain 4. The genes encoding calpains 2
and 4, Capn2 and Capn4, are essential (92–94). In contrast,
calpain 1 knockout mice are viable and fertile (95). Calpain 3
is a muscle-specific isoform, but is not essential (34).
However, mutations in human calpain 3 (CAPN3), are known
to cause limb girdle muscular dystrophy, type 2A (58).
Notably, patients with mutations in CAPN3 have been misdiag-
nosed with SMA type III (96), illustrating a degree of phenoty-
pic overlap between the two diseases. Although calpain 3 is a
sarcomeric protein, it is not thought to localize to the Z-disc
(97,98). Thus, while we do not anticipate that SMN is a
target of calpain 3, additional experiments will be required to
address the question of which calpains cleave SMN in vivo.
The structural cues for cleavage by calpain are incompletely
understood, as the protease does not have a clear target site
preference. Instead, 3D features within the substrate (99,100)
as well as the sequence context (101,102) appear to be more
important than the actual scissile peptide linkage. Although
we have not mapped the precise cleavage site on SMN, the
epitope for the monoclonal antibody used to identify the
10 kDa C-terminal cleavage product lies within the region
encoded by exon 5 of the human gene (L. Pellizzoni, unpub-
lished data). We therefore place the cleavage site of the
human protein somewhere between amino acids 190 and
230, separating the N-terminal Tudor domain of SMN from
its C-terminal Y-G box motif.
Importantly, the C-terminal domain of SMN (residues
235–294) has been implicated in regulating the G- to
F-actin ratio, and expression of this C-terminal fragment can
rescue neurite outgrowth defects in PC-12 cells that have
been depleted of endogenous Smn (8). Moreover, SMN was
shown to modulate the inhibitory effect of profilin IIa on spon-
taneous actin polymerization in vitro (13). SMN was also
shown to associate with the actin cytoskeleton in fibroblasts
(103) and to colocalize with F-actin in neuronal growth
cones (21). Finally, regulation of the actin cytoskeleton was
recently shown to be a key factor in SMA type III pathology,
as overexpression of an F-actin stabilizing protein rescued the
disease phenotype in humans (104). These results firmly estab-
lish the importance of actin cytoskeletal dynamics in SMN
function and SMA pathology. Calpains are ubiquitously
expressed and are important for the function of many cell
types, including neurons. Thus the identification of SMN as
a target of calpain cleavage is of general interest. In the
future, it will be interesting to test whether proteolytic iso-
forms of SMN play a role in actin cytoskeletal dynamics.
Figure 9. SMA type 1 mice have aberrant myofibrils. Muscle fibers from SMA
and wild-type littermates (A, B) were fixed and then stained with an antibody
against a-actinin (average projection of a Z-stack of 18 focal planes at 0.5 mm
per section) and compared (C). See text for details.
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MATERIALS AND METHODS
Mouse lines and crosses
Wild-type strains of FVB/NJ, C57BL/6J and 129 genetic
backgrounds were used throughout the study. FVB.Cg-
Tg(SMN2)89Ahmb Smntm1Msd/J mice carrying the SMA
allele were obtained from the Jackson Laboratory. All strains
were maintained on a standard diet of 50/10 food pellets and
sterile water. These mice were housed in micro-isolation
chambers. Breeding pairs consisted of mice that were homo-
zygous for the transgene and heterozygous for the knockout
allele, which resulted in pups that display the SMA phenotype
and control littermates. All mice were humanely euthanized
according to protocols set forth by Institutional Animal Care
and Use Committee (IACUC) standards.
Antibodies
The antibodies used are as follows: anti-a-actinin (Abcam),
anti-Gemin 2 (2E17, Abcam), anti-Gemin 3 (12H12), anti-
Gemin 4 (30-H3), anti-Gemin 6 (20H8-E5), anti-Gemin 8
(1F8-B6), anti-neurofilament-L (DA2, Cell Signaling),
anti-SmB (125F), N-terminal anti-SMN (Clone 8, BD bio-
science), C-terminal anti-SMN (9F2) and anti-Unrip (3G6).
Western blotting
Muscle, myofibril and cell lystates were prepared, electrophor-
esed, and blotted using standard protocols. Antibodies directed
against Smn (anti-mouse, 1:2500; BD biosciences) and GST
(anti-mouse, 1:3000) were used. Goat anti-mouse secondary
conjugated to horseradish peroxidase (HRP) was used for
detection at a dilution of 1:10 000. Detection of His-SMN
was carried out by use of Ni conjugated to HRP (Peirce) at
a dilution of 1:5000.
Immunofluorescence
Muscle fibers were prepared primarily from excision of the gas-
trocnemius of P5 pups. Muscle fibers were fixed in 4% parafor-
maldehyde/1X Triton X-100. Myofibrils were prepared from
striated muscle taken from adult mice, which were subsequently
fixed in 4% formaldehyde. Immunostaining was performed fol-
lowing established protocols. Certain preparations were also
stained for filamentous actin by adding 1 mM FITC-conjugated
phalloidin (Sigma-Aldrich) 20 min before the secondary anti-
body incubation was complete. Images were taken using
either a TCS SP2 laser scanning confocal microscope or a
DM6000 microscope (both Leica), and assembled using Photo-
shop (Adobe). The Leica Confocal Scanner is interfaced with
Leica Confocal Software, and the DM6000 microscope is inter-
faced with Volocity software.
Myofibril preparations and staining
Mouse skeletal and cardiac myofibrils were prepared by
following the protocols of Knight and Trinick (105). Striated
muscle was depleted of calcium by incubating overnight in
EGTA-Ringer’s solution (100 mM NaCl, 2 mM KCl, 2 mM
MgCl2, 6 mM KH2PO4, 1 mM EGTA, 0.1% glucose, pH 7.0
at 08C) at 48C. The samples were then transferred to rigor
buffer (0.1 M KCl, 2 mM MgCl2, 1 mM EDTA, 0.5 mM DTT
added fresh each time, 10 mM KH2PO4, pH 7.0 at 08C) and
homogenized using a glass Dounce tissue grinder. The hom-
ogenate was cleared of cell membrane and other debris
when spun at 200g for 5 min. The resulting supernatant was
then spun at 2000g for 5 min and washed by repeated cycles
until a pure preparation of myofibrils (as monitored by phase-
contrast microscopy) was obtained. Purified myofibrils were
used for western blotting or were fixed to gelatin coated
slides (0.05%) and subjected to immunofluorescence analysis
using standard protocols. Note that for dual staining of Smn
and a-actinin or Gemins, mouse monoclonal antibodies were
incubated with purified myofibrils, followed by incubation
with secondary antibodies conjugated to Alexa Fluor 594. Fol-
lowing extensive washing, the preparations were incubated
with FITC-conjugated monoclonal anti-SMN antibodies.
Calpain treatments
Cell lysates prepared in a gentle binding buffer (50 mM Tris
pH 7.5, 200 mM NaCl, 0.2 mM EDTA, 0.05% NP40) were
incubated with either calpain 1 or calpain 2 (Calbiochem) at
1.4 units for 10 min at 308C. Note for each reaction 1 mM
CaCl2 is used to activate the calpain protease. The resulting
lysates were then electrophoresed and analyzed by standard
western blot procedures. Purified SMN complexes and
His-SMN/GST-Gemin 2 heterodimers were treated with
calpain as described earlier with the following exception:
0.003–0.3 units of calpain 1 were used. Myofibril preps
were incubated in 1 ml of calcium activating buffer (100 mM
KCl, 20 mM Tis-acetate pH 7.0, 10 mM CaCl2, 1 mM NaN3)
with calpain 1 (,40 units), for 30 min at RT on a nutator.
After incubation the myofibrils were spun down and washed
3 in rigor buffer at 2000g at 48C and fixed to slides.
When activation of endogenous calpains was analyzed fresh
skeletal muscle was incubated in calcium activating buffer
overnight at RT on a nutator. The muscle tissue was then pre-
pared for myofibril extraction as described earlier. Standard
immunostaining protocols were used for analysis.
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Supplementary Material is available at HMG Online.
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